Basis: FMP quote market capitalization / four-quarter operating cash flow less absolute capital expenditures. Source: stored company filings and market data; unavailable inputs remain N/A.
The Price/FCF ratio is N/A as of 2026-10-06T16:08:13.263Z.
Calculation as of: 2026-10-06T16:08:13.263Z.
Quote observation: 2026-10-06T16:05:14.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 7de7752a9f7c92cf302168b3adc2b8952dbd3ee015c15fa7e623ade4200d4f53
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PRICE/FCF RATIO
N/A
Market Cap
$826.20M
Price/FCF Ratio
N/A
TTM Avg
198.42
3Y Avg
198.42
5Y Avg
198.42
Market Cap
$802.42M
Price/FCF Ratio
N/A
TTM Avg
424.04
3Y Avg
254.96
5Y Avg
216.79
Market Cap
$841.48M
Price/FCF Ratio
N/A
TTM Avg
104.86
3Y Avg
47.92
5Y Avg
28.61
| NAME | MARKET CAP | PRICE/FCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Jade Biosciences, Inc. (JBIO) | $825.57M | N/A | N/A | N/A | N/A |
| Pacific Biosciences of California, Inc. (PACB)vs › | $826.20M | N/A | 198.42 | 198.42 | 198.42 |
| Ardelyx, Inc. (ARDX)vs › | $813.54M | N/A | 8.01 | 8.93 | 8.93 |
| Alumis Inc. (ALMS)vs › | $839.96M | N/A | N/A | N/A | N/A |
| InMode Ltd. (INMD)vs › | $805.59M | 9.21 | 9.91 | 9.93 | 15.12 |
| Beta Bionics, Inc. (BBNX)vs › | $844.46M | N/A | N/A | N/A | N/A |
| Gyre Therapeutics, Inc. (GYRE)vs › | $802.42M | N/A | 424.04 | 254.96 | 216.79 |
| QuidelOrtho Corporation (QDEL)vs › | $841.48M | N/A | 104.86 | 47.92 | 28.61 |
| Apnimed, Inc. (APMD)vs › | $792.48M | N/A | N/A | N/A | N/A |
| AdaptHealth Corp. (AHCO)vs › | $797.41M | 8.16 | 7.03 | 12.33 | 28.28 |
P/FCF Ratio
N/A
FCF Yield
N/A
P/FCF measures market price relative to free cash flow per share. Free cash flow is operating cash flow after capital expenditures.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
